Trial Profile

A phase 3, randomized, double-blind, placebo-controlled, parallel-group, study to evaluate efficacy and safety of GK567 in patients with rosacea

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 15 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Metronidazole (Primary)
Indications Rosacea
Focus Registrational; Therapeutic Use
Sponsors Maruho

Most Recent Events

01 Mar 2022 Primary endpoint (The proportion of subjects achieving the treatment success at week 12) has been met, according to Results published in the Journal of Dermatology.
01 Mar 2022 Results published in the Journal of Dermatology
24 Dec 2021 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com